Tore K Kvien - Concepedia

Author

Tore K Kvien

Also Known As

A. Kavanaugh, Bruno Fautrel, D. van der Heijde, Dan Nordstrm, Helga Sanner, Kvien, T.K., Kvien, Tore K., Laure Gossec, Paolo Airo, T K Kvien

846

Publications

54.6K

Citations

109

H-Index

128

Concepts

All Affiliations

Diakonhjemmet Hospital University of Oslo Oslo University Hospital Leiden University Medical Center St Olav's University Hospital

About

Tore K Kvien is an author at Diakonhjemmet Hospital specializing in medicine, rheumatology, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	57	5.6K
2	Public Health	6	6	230
3	Health Sciences	5	5	1.1K
4	Engineering	3	3	437
5	Nursing	2	2	276

Tore K Kvien

385

Publications

41.9K

Citations

100

H-Index

Page 1

	Year	Citations
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis Claire Bombardier, Loren Laine, Alise Reicin, New England Journal of Medicine	2000	4K
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld, Annals of the Rheumatic Diseases	2013	1.8K
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis M.J. Peters, Deborah Symmons, David McCarey, Annals of the Rheumatic Diseases	2009	1.3K
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials David T. Felson, Josef S Smolen, George A. Wells, Arthritis & Rheumatism	2011	1K
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll, The Lancet OncologyClinical TranslationOriginator InfliximabClinical TrialsClinical Evidence	2017	789
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial Josef S Smolen, Joachim R. Kalden, David L. Scott, The Lancet Rheumatoid DisorderRheumatologyAnti-inflammatoryMedicineRheumatic Diseases	1999	769
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores Pedro Machado, Robert Landewé, E. Lie, Annals of the Rheumatic Diseases	2010	769
Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis register Glenn Haugeberg, Till Uhlig, Jan A. Falch, Arthritis & Rheumatism	2000	680
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force Josef S Smolen, Monika Schöls, Jürgen Braun, Annals of the Rheumatic Diseases	2017	662
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis Désirée van der Heijde, E. Lie, Tore K Kvien, Annals of the Rheumatic Diseases	2008	619

Page 1